AcuSense BioMedical Technology Corp. is committed to providing a safer medical enviornment for patients and healthcare professionals in the world. Our product combines wearable medical device, multi-bed IoT monitor system and A.I.-based algorithm to effectively improve medical safety and quality of care. Our product can be used in home dialysis, acute and critical IV-line safety, chemotherapy injection and ICU safety. In the future, we plan to deploy smart AIoMT solutions into the global catheter safety market. The company was founded in 2017 and has operations in Tainan Science Park in Taiwan and Silicon Valley in the United States.
The core philosophy of AcuSense Biomedical fully echoes the World Health Assembly agenda on Patient Safety. Our team has won many awards including National Innovation Award, Ministry of Science and Technology Potential Award, Startup Raising Star, AIGO Competition award, and SNQ quality certification. In 2018, Acusense was selected to enter the Southern Science Park and passed ISO 13485 certification. In 2019, application to conduct clinical trial in Taiwan was approved. Acusense is conducting discussion with medical institutions, sales channels, and development units in Singapore, Sweden, and the United States.
[Strategy Partners and Consultants]
Acusense Biomedical’s strategic shareholders include manufacturing plants of GMP / ISO 13845 / D-U-N-S® Registere certificated, former Asia region president of an international medical materials company, patent attorney and lawyer, financial consultant (CFA certified) and regulatory specialists. We are an ambitious professional team and all employees are also shareholders. Clinical consultants include experienced clinicians in nephrology, cardiology, and internal medicine in the United States and Taiwan.
Cooperation projects and needs
1. Fundraising and investment cooperation for $1M to implement relevant product about regulations and certifications to enter the market
2. Collaborating on smart medical AI research projects, Acusense
Biomedical has an AI team to assist in computational modeling.
3. The international channel for hemodialysis and ICU and strategic cooperation to enter the global market.